TR200100144T2 - Farmasötik aerosol formülasyonu - Google Patents

Farmasötik aerosol formülasyonu

Info

Publication number
TR200100144T2
TR200100144T2 TR2001/00144T TR200100144T TR200100144T2 TR 200100144 T2 TR200100144 T2 TR 200100144T2 TR 2001/00144 T TR2001/00144 T TR 2001/00144T TR 200100144 T TR200100144 T TR 200100144T TR 200100144 T2 TR200100144 T2 TR 200100144T2
Authority
TR
Turkey
Prior art keywords
pharmaceutical aerosol
aerosol formulation
therapeutic agent
relates
formulations
Prior art date
Application number
TR2001/00144T
Other languages
English (en)
Inventor
Cavaillon Pascal
Llorca Nathalie
Louis Olivier
Rosier Patrick
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200100144T2 publication Critical patent/TR200100144T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, asagidaki kisimlari içeren yeni farmasötik aerosol formülasyonlarina ve bu formülasyonlarin hazirlanmasi için bir isleme iliskindir: (A) en azindan bir kaplama ilaç yardimci maddesi ve en azindan bir sürfaktan ile kaplanmis parçaciklar biçiminde bir terapötik madde, (B) özellikle soluma yolu ile terapötik maddelerin tatbikati için bir sivilastirilmis sevk gazi. Bulus ayni zamanda bu formülasyonlarda kullanim için müsait yeni parçaciklara da iliskindir.
TR2001/00144T 1998-04-18 1999-04-15 Farmasötik aerosol formülasyonu TR200100144T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
TR200100144T2 true TR200100144T2 (tr) 2001-06-21

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00144T TR200100144T2 (tr) 1998-04-18 1999-04-15 Farmasötik aerosol formülasyonu

Country Status (30)

Country Link
US (1) US7521042B2 (tr)
EP (1) EP1073417B1 (tr)
JP (1) JP2002512183A (tr)
KR (1) KR20010042816A (tr)
CN (1) CN1145478C (tr)
AP (1) AP2000001961A0 (tr)
AR (1) AR018183A1 (tr)
AT (1) ATE228823T1 (tr)
AU (1) AU755066B2 (tr)
BR (1) BR9909736A (tr)
CA (1) CA2328882A1 (tr)
CO (1) CO5021210A1 (tr)
DE (1) DE69904312T2 (tr)
DK (1) DK1073417T3 (tr)
EA (1) EA200000956A1 (tr)
EE (1) EE200000608A (tr)
ES (1) ES2189410T3 (tr)
HR (1) HRP20000689A2 (tr)
HU (1) HUP0101608A2 (tr)
ID (1) ID27887A (tr)
IL (1) IL139087A0 (tr)
IS (1) IS5665A (tr)
MA (1) MA26621A1 (tr)
NO (1) NO20005218L (tr)
NZ (1) NZ507619A (tr)
PE (1) PE20000433A1 (tr)
PL (1) PL343491A1 (tr)
PT (1) PT1073417E (tr)
TR (1) TR200100144T2 (tr)
WO (1) WO1999053901A1 (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
EP2283817B1 (en) † 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
KR20050088175A (ko) * 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
AU2004240640A1 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
BRPI0606364A2 (pt) * 2005-02-10 2010-03-23 Glaxo Group Ltd processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
SG178036A1 (en) 2009-07-15 2012-03-29 Theravance Inc Crystalline freebase forms of a biphenyl compound
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
WO2011155451A1 (ja) * 2010-06-08 2011-12-15 学校法人神戸学院 コーティング粒子及びコーティング粒子の製造方法
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
ES2053549T3 (es) * 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
ES2191101T3 (es) * 1995-06-12 2003-09-01 Ono Pharmaceutical Co Granulos que contienen pranlukast, procedimiento de produccion de los granulos y procedimiento de reduccion de la cohesion del pranlukast.
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6001336A (en) * 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof

Also Published As

Publication number Publication date
EP1073417A1 (en) 2001-02-07
IL139087A0 (en) 2001-11-25
US7521042B2 (en) 2009-04-21
AP2000001961A0 (en) 2000-12-31
KR20010042816A (ko) 2001-05-25
PT1073417E (pt) 2003-04-30
JP2002512183A (ja) 2002-04-23
NO20005218D0 (no) 2000-10-17
AU3523199A (en) 1999-11-08
WO1999053901A1 (en) 1999-10-28
NO20005218L (no) 2000-11-10
CN1305369A (zh) 2001-07-25
DE69904312D1 (de) 2003-01-16
HRP20000689A2 (en) 2001-02-28
DK1073417T3 (da) 2003-03-24
EP1073417B1 (en) 2002-12-04
AU755066B2 (en) 2002-12-05
DE69904312T2 (de) 2003-10-16
NZ507619A (en) 2003-05-30
ES2189410T3 (es) 2003-07-01
EA200000956A1 (ru) 2001-04-23
CA2328882A1 (en) 1999-10-28
ATE228823T1 (de) 2002-12-15
AR018183A1 (es) 2001-10-31
CO5021210A1 (es) 2001-03-27
MA26621A1 (fr) 2004-12-20
IS5665A (is) 2000-10-13
CN1145478C (zh) 2004-04-14
US20030157032A1 (en) 2003-08-21
ID27887A (id) 2001-05-03
PL343491A1 (en) 2001-08-27
BR9909736A (pt) 2000-12-19
EE200000608A (et) 2001-08-15
HUP0101608A2 (hu) 2002-03-28
PE20000433A1 (es) 2000-05-26

Similar Documents

Publication Publication Date Title
EE9900075A (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
DE69233150D1 (de) Fluorchlorkohlenwasserstoffreie Aerosolformulierungen
BG105033A (bg) Фармацевтични състави за аерозоли с две, или повече активни вещества
DE60230035D1 (de) Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
EP0873141A4 (en) COMPOSITIONS AND METHODS FOR THERAPEUTIC USE
EE200000380A (et) 11ß-halogeno-7(alfa)-asendatud östratrieenid, neid 11ß-halogeno-7(alfa)-asendatud östratrieene sisaldavate farmatseutiliste preparaatide valmistamise meetodid ja nende kasutamine ravimite valmistamiseks
BR9909736A (pt) Formulação farmacêutica de aerossol, processo para preparação de uma formulação farmacêutica de aerossol, partìculas de princìpios ativos farmacêuticos, e, cartucho
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
ATE234274T1 (de) Derivate des adamantan
SE9700135D0 (sv) New formulation
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
EE200100037A (et) Bensotsüklohepteenid, nende valmistamise meetod, neid sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
TR199903191T2 (tr) Vorikonazol içeren ilaç formülasyonlari.
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
BR0212857A (pt) Formulações e uso destas
EE04238B1 (et) Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias
HUP0301349A2 (hu) IL-11-tartalmú készítmények
ATE329608T1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
DE60019334D1 (de) Antivirale arznei
TR199900379T2 (tr) Klorofluorokarbon içermeyen mometazon furoat aerosol formülasyonlari.
BR9711896A (pt) Uso de um inibidor h+,k+atpase e um glicocorticÄide processos para o tratamento de um pÄlipo nasal da sindrome de widal e de asma e formula-{es farmac-uticas para uso sumult-neo separado ou sequencial no tratamento da s¡ndrome de widal e para administra-Æo simult-nea separada ou sequencial no tratamento da asma
ECSP088732A (es) Aerosoles dosificadores para la administración de preparaciones farmacéuticas
BR0012184B1 (pt) compostos derivados de indol, formulação farmacêutica, e, composição e uso dos compostos na fabricação de medicamentos
NO323466B1 (no) Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater